Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Product Liability Law & StrategyKickerFeaturesSectionsNewsLJN Newsletters

A Plaintiff's Perspective

By Vance R. Andrus and Richard J. Arsenault
June 14, 2005

Dr. David Graham, a courageous FDA expert, blew the whistle and started a cascade of events that ultimately led to Merck & Co., Inc.'s withdrawal of its blockbuster drug Vioxx. Recently, he testified in Congress that Vioxx could be “the single greatest drug catastrophe of this country.” Various experts have postulated that Vioxx may be directly responsible for 20,000 to 160,000 heart attacks or strokes with perhaps as many as 40,000 deaths.

What happened? Should Merck be held responsible? This article, which is a condensation of a paper presented at a national Vioxx conference in November 2004, will present a very brief overview of the Vioxx controversy from a plaintiff's perspective. Portions in quotations are taken from the “Plaintiffs' Initial Statement/Position Paper,” prepared by the members of the PSC Executive Committee and filed in In Re: Vioxx Products Liability Litigation, MDL 1657, USDC ED, LA.

This premium content is locked for Entertainment Law & Finance subscribers only

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473

Read These Next
The DOJ's Corporate Enforcement Policy: One Year Later Image

The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.

Use of Deferred Prosecution Agreements In White Collar Investigations Image

This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.

The DOJ's New Parameters for Evaluating Corporate Compliance Programs Image

The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.

How AI Has Affected PR Image

When we consider how the use of AI affects legal PR and communications, we have to look at it as an industrywide global phenomenon. A recent online conference provided an overview of the latest AI trends in public relations, and specifically, the impact of AI on communications. Here are some of the key points and takeaways from several of the speakers, who provided current best practices, tips, concerns and case studies.

CLE Shouldn't Be the Only Mandatory Training for Attorneys Image

Each stage of an attorney's career offers opportunities for a curriculum that addresses both the individual's and the firm's need to drive success.